Force-plate quantification of progressive behavioral deficits in the R6/2 mouse model of Huntington's disease

Behavioural Brain Research

Volumn 202, Issue 1, 2009, Pages 130-137

  Fowler, Stephen C ^a   Miller, Benjamin R ^b   Gaither, Thomas W ^b   Johnson, Michael A ^a   Rebec, George V ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Dysrhythmia; Force plate; Gait; Huntington's disease; Locomotion; Mouse; Wall rears

Indexed keywords

ALGORITHM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; BODY WEIGHT; COMPUTER; CONTROL GROUP; CONTROLLED STUDY; DISEASE COURSE; DYSMETRIA; FEMALE; GAIT; HUNTINGTON CHOREA; MALE; MOUSE; NONHUMAN; PHENOTYPE; POWER SPECTRUM; PRIORITY JOURNAL; RADIUS; RHYTHM; WILD TYPE;

AGE FACTORS; ALGORITHMS; ANIMALS; BODY WEIGHT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FOURIER ANALYSIS; GENOTYPE; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MOVEMENT DISORDERS; NERVE TISSUE PROTEINS; NEUROPSYCHOLOGICAL TESTS; NUCLEAR PROTEINS; PHENOTYPE; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 67349152756     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.03.022     Document Type: Article

References (31)

1. Aziz N.A., van der Burg J.M., Landwehrmeyer G.B., Brundin P., Stijnen T., Roos R.A., and E.H.D.I. StudyGroup. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 71 (2008) 1506-1513
2. Baik J.H., Picetti R., Saiardi A., Thiriet G., Dierich A., Depaulis A., et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377 (1995) 424-428
3. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19 (1999) 3248-3257
4. Clarke K.A., Smart L., and Still J. Ground-reaction force and spatiotemporal measurements of the gait of the mouse. Behav Res Methods Instrum Comput 33 (2001) 422-426
5. Dragatsis I, Goldowitz D, Del Mar N, Deng YP, Meade CA, Liu L, Sun Z, Dietrich P, Yue J, Reiner A. CAG repeat lengths ≥ 335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse. Neurobiol Dis; November 2008. Epub ahead of print.
6. Fowler S.C., Birkestrand B.R., Chen R., Moss S.J., Vorontsova E., Wang G., et al. A force-plate actometer for quantitating rodent behaviors: illustrative data on locomotion, rotation, spatial patterning, stereotypies, and tremor. J Neurosci Methods 107 (2001) 107-124
7. Fowler S.C., Zarcone T.J., Vorontsova E., and Chen R. Motor and associative deficits in D2 dopamine receptor knockout mice. Int J Dev Neurosci 20 (2002) 309-321
8. Herbin M., Gasc J.P., and Renous S. Symmetrical and asymmetrical gaits in the mouse: patterns to increase velocity. Comp Physiol A: Neuroethol Sens Neural Behav Physiol 190 (2004) 895-906
9. Hickey M.A., Gallant K., Gross G.G., Levine M.S., and Chesselet M.F. Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol Dis 20 (2005) 1-11
10. Hockly E., Cordery P.M., Woodman B., Mahal A., van Dellen A., Blakemore C., et al. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann Neurol 51 (2002) 235-242
11. Hockly E., Woodman B., Mahal A., Lewis C.M., and Bates G. Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res Bull 61 (2003) 469-479
12. Lloret A., Dragileva E., Teed A., Espinola J., Fossale E., Gillis T., et al. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice. Hum Mol Genet 15 (2006) 2015-2024
13. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
14. Mangiarini L., Sathasivam K., Mahal A., Mott R., Seller M., and Bates G.P. Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation. Nat Genet 15 (1997) 197-200
15. Menalled L.B., Sison J.D., Dragatsis I., Zeitlin S., and Chesselet M.F. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 465 (2003) 11-26
16. Menalled L.B. Knock-in mouse models of Huntington's disease. NeuroRx 2 (2005) 465-470
17. Miller B.R., Dorner J.L., Shou M., Sari Y., Barton S.J., Sengelaub D.R., et al. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 153 (2008) 329-337
18. Muir G.D., and Whishaw I.Q. Ground-reaction forces in locomoting hemi-parkinsonian rats: a definitive test for impairments and compensations. Exp Brain Res 126 (1999) 307-314
19. Rao A.K., Muratori L., Louis E.D., Moskowitz C.B., and Marder K.S. Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease. Mov Disord 23 (2008) 1100-1107
20. Rebec G.V., Barton S.J., and Ennis M.D. Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene. J Neurosci 22 (2002) RC202
21. Rebec G.V., Barton S.J., Marseilles A.M., and Collins K. Ascorbate treatment attenuates the Huntington behavioral phenotype in mice. Neuroreport 14 (2003) 1263-1265
22. Schilling G., Savonenko A.V., Coonfield M.L., Morton J.L., Vorovich E., Gale A., et al. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp Neurol 187 (2004) 137-149
23. Schilling G., Coonfield M.L., Ross C.A., and Borchelt D.R. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett 315 (2001) 149-153
24. Stack E.C., Kubilus J.K., Smith K., Cormier K., Del Signore S.J., Guelin E., et al. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J Comp Neurol 490 (2005) 354-370
25. van Dellen A., Cordery P.M., Spires T.L., Blakemore C., and Hannan A.J. Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease. BMC Neurosci 9 (2008) 34
26. van Dellen A., Blakemore C., Deacon R., York D., and Hannan A.J. Delaying the onset of Huntington's in mice. Nature 404 (2000) 721-722
27. van Raamsdonk J.M., Metzler M., Slow E., Pearson J., Schwab C., Carroll J., et al. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol Dis 26 (2007) 189-200
28. von Hörsten S., Schmitt I., Nguyen H.P., Holzmann C., Schmidt T., Walther T., et al. Transgenic rat model of Huntington's disease. Hum Mol Genet 12 (2003) 617-624
29. Walker F.O. Huntington's disease. Lancet 369 (2007) 218-228
30. Wu J., Zou H., Strong J.A., Yu J., Zhou X., Xie Q., et al. Bimodal effects of MK-801 on locomotion and stereotypy in C57BL/6 mice. Psychopharmacology (Berl) 177 (2005) 256-263
31. Zumwalt A.C., Hamrick M., and Schmitt D. Force-plate for measuring the ground reaction forces in small animal locomotion. J Biomech 39 (2006) 2877-2881